The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Avacta Group's share price is £0.725.
Avacta Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was £0.00. Hence, Avacta Group's PS Ratio for today is .
The historical rank and industry rank for Avacta Group's PS Ratio or its related term are showing as below:
During the past 13 years, Avacta Group's highest PS Ratio was 272.91. The lowest was 3.81. And the median was 34.19.
LSE:AVCT's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.64 * Ranked among companies with meaningful PS Ratio only.
During the past 13 years, Avacta Group's highest 3-Year average Revenue per Share Growth Rate was 206.60% per year. The lowest was -44.90% per year. And the median was -3.30% per year.
Back to Basics: PS Ratio
Avacta Group (LSE:AVCT) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Avacta Group PS Ratio Related Terms
Avacta Group PS Ratio Historical Data
* Premium members only.
The historical data trend for Avacta Group's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Avacta Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avacta Group PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avacta Group's PS Ratio distribution charts can be found below:
* The bar in red indicates where Avacta Group's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Avacta Group's PS Ratio for today is calculated as
Avacta Group's Share Price of today is £0.725.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Avacta Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was £0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued.
The current stock price of £0.73 is trading 48% above its estimated GF Value™ of £0.49.
GuruFocus considers Avacta Group to be Significantly Overvalued.
Key valuation signals for LSE:AVCT:
PS Ratio:
GF Value™: £0.49 vs. price of £0.73 (48% above fair value)
No single metric tells the full story. See the LSE:AVCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
28GF Score
Get the complete analysis for LSE:AVCT
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:AVCT has been successfully added to your 
